BahledaR, Meric-BernstamF, GoyalL, et al.. Phase 1, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors [published online July 2, 2020]. Ann Oncol, doi:10.1016/j.annonc.2020.06.018
BahledaR, Meric-BernstamF, GoyalL, . Phase 1, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors [published online July 2, 2020]. Ann Oncol, doi:10.1016/j.annonc.2020.06.01832622884)| false
MulcahyAW, HlavkaJP, CaseSR. Biosimilar cost savings in the United States: initial experience and future potential. RAND Corporation. Accessed July 10, 2020. Available at: https://www.rand.org/pubs/perspectives/PE264.html
MulcahyAW, HlavkaJP, CaseSR. Biosimilar cost savings in the United States: initial experience and future potential. RAND Corporation. Accessed July 10, 2020. Available at: https://www.rand.org/pubs/perspectives/PE264.html)| false
